Hand-foot syndrome and seborrheic dermatitis-like eruption induced by erlotinib

Department of dermatology, Ibn Sina Hospital, Mohamed V University of Rabat, Morocco.
Dermatology online journal 11/2009; 15(11):2.
Source: PubMed


Erlotinib is an epidermal growth factor receptor tyrosine kinase inhibitor that is responsible for several cutaneous side effects. We report a case of hand-foot syndrome associated with a papulo-pustular and seborrheic dermatitis-like eruption of the face in a 61-year-old patient treated with erlotinib for lung cancer.

1 Follower
24 Reads
  • Source
    [Show abstract] [Hide abstract]
    ABSTRACT: Icotinib is a new oral epidermal growth factor tyrosine kinase inhibitor (EGFR-TKI). The most frequent side-effects of icotinib include rash and diarrhea. Hand-foot syndrome (HFS) induced by EGFR-TKI is rare. The present study describes, for the first time, HFS induced by high-dose icotinib in a 65-year old female with metastatic lung adenocarcinoma. The patient developed HFS during the first week of icotinib treatment with characteristic clinical presentation. HFS regressed after icotinib dose-reduction was initiated. HFS may occur with icotinib, especially when administered in high doses.
    Oncology letters 12/2012; 4(6):1341-1343. DOI:10.3892/ol.2012.904 · 1.55 Impact Factor
  • [Show abstract] [Hide abstract]
    ABSTRACT: Introduction Erlotinib, an epidermal growth factor receptor tyrosine kinase inhibitor (EGFR-TKI), is a targeted therapy used in first, second or third line treatment of non-small cell lung carcinoma. Several cutaneous toxicities after the use of EGFR-TKI are well-described. Observation After 13 days of erlotinib treatment, an 82-year-old man, diagnosed with squamous cell lung carcinoma, developed an acneiform rash in parallel with hand-foot syndrome (HFS). This led to the interruption of his treatment because of the patient's distress. However, for the first time and after a total recovery of the toxidermia, we reintroduced the therapy at very low doses without any HFS recurrence being observed. Discussion The HFS is a dose-dependent toxidermia appearing within the first week following administration of the triggering cytotoxic agents (chemotherapies or target therapies). It appears that a specific pathogenic mechanism exists for each cytotoxic agent triggering the skin damage, resulting in different clinical presentations. A major aspect of HFS treatment involves the reduction or withdrawal of the treatment. Conclusions We describe what is to our knowledge, the third case of erlotinib-induced HFS, a new secondary undesirable skin pathology for which, currently, exist few direct causal explanations or drug monitoring. This observation highlights the importance of broadening our knowledge of the exact mechanisms linking EGFR-TKI to the appearance of HFS in order to optimize treatment.
    Revue des Maladies Respiratoires 01/2013; 31(7). DOI:10.1016/j.rmr.2013.11.006 · 0.62 Impact Factor

  • International journal of dermatology 05/2013; 53(3). DOI:10.1111/j.1365-4632.2012.05780.x · 1.31 Impact Factor
Show more